In Segment C, contributors will acquire ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or perhaps the members are unable to tolerate the study drugs. Celastrol was discovered for a Myb inhibitor that suppressed C/EBPβ exercise and https://erickcffcx.blog-kids.com/32190629/little-known-facts-about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers